Press Releases

02-05 Neurogene to Participate in Upcoming Investor Conferences BU
02-04 Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BU
01-14 Neurogene : 2026 JP Morgan Presentation PU
01-12 Neurogene : Corporate Presentation January 2026 PU
01-12 Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome BU
01-05 Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference BU
12-04 Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BU
11-13 Neurogene : 202511 NGNE Corporate Presentation PU
11-13 Neurogene: Q3 Earnings Snapshot AQ
11-13 Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates BU
11-12 Neurogene : NGN 401 2H25 Update FINAL PU
11-12 Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome BU
11-06 Neurogene : 202511 NGNE Corporate Presentation FINAL PU
11-06 Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome BU
11-05 Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BU
09/10/25 Neurogene : ESGCT 2025 HLH Combined vFinal Print PU
09/10/25 Neurogene : 202510 NGNE Corporate Presentation FINAL PU
09/10/25 Neurogene : Poster ESGCT2025 RoA Final Print PU
09/10/25 Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025 BU
08/10/25 Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference BU
06/10/25 Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635c4 AQ
06/10/25 Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) AQ
03/10/25 Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BU
05/09/25 Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BU
12/08/25 Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 8, 2025 AQ
No results for this search